Intra-Cellular Therapies (“ITCI”) Stock Soars While Key Clinical Data Not Presented to Shareholders Looks Highly Disappointing

(July 15th, 2015) Biotech stocks have been on fire. And for good reason as numerous life-saving discoveries have come out of small, previously-unknown firms, making their owners rich many times over. But beneath the surface, a number of troubling drug development companies have caught the attention of investors with clinical data that’s dubious at best. With seemingly endless amounts of optimism, these biotech stocks have ridden the wave of investor enthusiam even when the data doesn’t look as promising as the market caps seem to indicate.

Read more

All You Ever Wanted to Know About Retrophin But Were Afraid to Ask

(June 2nd, 2014) Humans, like atoms, abhor unsteady states of existence. Just like electron transport gravitates towards a steady-state, people gravitate towards peaceful lands and away from battleground areas. Read more

Know What to Buy When Putin Comes Knocking

So Putin rolls a bunch of tanks up to the Ukrainian border and the market slides a percent or so. In any other market that would be considered a yawn. But here in the good ‘ol US of A, where the average active investor can barely remember the dog days of ’08, few traders seem to have the skill set necessary to maneuver in a down market. Having done this for 20+ years, I thought it would be helpful to share my trading tips for when war comes knocking.
Read more

Little Bear Research is born out of the more than 14 years our principal, Zachary Prensky, has worked as both a lead investor and investment banker in emerging high growth companies both in the US and abroad. Zachary has raised capital for, invested directly, or sat on the Board of Directors of over 60 emerging market companies. This experience has focused his lens on the time-honored investment criteria of leadership, integrity, transparency and execution.

With the rise of Asia and other emerging market economies, a number of businesses have been listed on the US stock exchanges that mimic in some sense the high growth characteristics of successful investments. However, Little Bear Research has discovered that in many cases these companies were lacking the key ingredients that are crucial to outperforming the overall market.

Little Bear is dedicated to highlighting companies that do not live up time honored investment criteria. In many cases, these companies deceive their own shareholders in the name of engineering short term equity performance. In the absence of an effective oversight mechanism – the SEC and other regulatory bodies have consistently ‘missed the boat’ in enforcing our countries rules and regulations – it falls to market participants such as Little Bear Research and others to bring the market’s attention to such institutional chicanery.

Little Bear accepts no fees or other payment from any market participants. We do not accept referrals or payments from any entity of any kind – our reporting is intended to be unbiased and free of influence. Little Bear strives to earn its reward off the back of its own research by taking long and short positions in equities that we cover. While we hold ourselves to the highest ethical standards of equity research please be aware that we trade for our own account(s) and may initiate or close positions at any time without updating our readers. All disclosures appended to research we publish is accurate only at the time of publication.

” Concentration is my motto – first honesty, then industry, then concentration. ” Andrew Carnegie